Synapse - Gastrointestinal Oncology Service

Results (4744)

Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

Meeting Abstract

Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)

Meeting Abstract

Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Meeting Abstract

Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, V. T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study

Meeting Abstract

Oaknin, A.; Ang, J. E.; Rha, S. Y.; Yonemori, K.; Kristeleit, R.; Lin, C. C.; Satoh, T.; Garcia, P. E.; Sendur, M. A. N.; Rodríguez, L. M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors

Meeting Abstract

Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Meeting Abstract

Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

Meeting Abstract

Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer

Meeting Abstract

Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)

Meeting Abstract

Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T.
Annals of Oncology (2024)

Fulltext@MSK | Save